Bio Arctic operates a hybrid model. It develops its own neuroscience drugs internally, but also licenses its 'brain transporter' technology as a platform to large pharma partners like Eli Lilly and Novartis. This creates a separate, de-risked revenue stream through milestones and royalties while validating their core technology.

To avoid common international growth pitfalls, Shift4 uses a capital-light strategy. Instead of building sales teams from scratch, it either partners with local distributors for a variable cost structure or acquires companies primarily for their proven, productive local sales forces.

For its $5k average deal size, SkillVari found a direct US sales model unviable, as travel costs could erase profits. Instead, they built a network of 10 regional resellers, incentivized with commissions up to 20%, to provide local, hands-on demos and support.

Basilea successfully acquires assets by focusing on the anti-infectives space, a niche often overlooked by big pharma. This strategy means they don't compete with larger companies for assets, allowing them to secure favorable, milestone-based deals that de-risk development and align costs with progress.

In the biosimilars industry, where prices inevitably decline over time, full vertical integration (from R&D to commercialization) is essential for survival. By controlling the entire value chain, companies like Biocon avoid profit-sharing with partners, preserving margins and enabling them to withstand market pressures that would cripple less integrated competitors.

Vivtex funded its growth and reached profitability not through traditional VC rounds, but by securing around 10 early pharma partnerships. This strategy provided significant non-dilutive revenue, reducing their reliance on investors and giving them more control over their trajectory—a powerful alternative to the typical biotech funding model.

Instead of building new sales teams for each product, Biocon maintains highly trained, specialized commercial teams focused on four core therapeutic areas: oncology, ophthalmology, immunology, and diabetes. This allows the company to efficiently launch new products within these pillars, leveraging existing expertise and infrastructure for scalable and repeatable commercial success.

For a biotech with an established commercial infrastructure, the most efficient growth strategy is to in-license late-stage or already-approved products. This leverages the existing sales force and operational teams to sell new products without adding significant overhead, maximizing operational efficiency and revenue.

Instead of raising large sums to hire a direct sales force, SmallTap partnered with regional specialty distributors. This strategy minimized equity dilution and leveraged existing sales relationships for broad market access without the high fixed costs of full-time employees.